Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06438172
Status:
RECRUITING
Last Update Posted:
2024-05-31
First Post:
2024-05-27
Brief Title:
A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients With Essential Hypertension
Sponsor:
Hanmi Pharmaceutical Company Limited
Organization:
Hanmi Pharmaceutical Company Limited
Study Overview
Official Title:
A Multicenter Randomized Double-blind Phase III Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients With Essential Hypertension
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HM_APOLLO
Brief Summary:
A multicenter randomized double-blind phase 3 study to evaluate efficacy and safety of HCP1803 compared to RLD2001-1 in patients with essential hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None